Effect of a novel 5-HT3 receptor antagonist carboxamide, 3-methoxy-N-p-tolylquinoxalin-2-carboxamide (QCM-4) on the acute and chronic rodent models of depression

International Journal of Pharmacy and Pharmaceutical Sciences

Volumn 5, Issue SUPPL 3, 2013, Pages 567-573

  Kurhe, Yeshwant Vijay ^a   Gupta, Deepali ^a   Thangaraj, Devodoss ^a   Mahesh, Radhakrishnan ^a  

^a BIRLA INSTITUTE OF TECHNOLOGY AND SCIENCE   (India)

Author keywords

5 HT3 antagonist; Depression; Head twich; Hypothermia; Immobility duration; OBX

Indexed keywords

3 METHOXY N P TOLYLQUINOXALIN 2 CARBOXAMIDE; 5 HYDROXYTRYPTOPHAN; AMFEBUTAMONE; ESCITALOPRAM; PARGYLINE; RESERPINE; SEROTONIN 3 ANTAGONIST; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIDEPRESSANT ACTIVITY; ARTICLE; CONTROLLED STUDY; DEPRESSION; FORCED SWIMMING TEST; LOCOMOTION; MALE; MOUSE; NONHUMAN; OLFACTORY BULBECTOMY; OPEN FIELD TEST; RAT; TAIL FLICK TEST;

EID: 84882757466     PISSN: None     EISSN: 09751491     Source Type: Journal    
DOI: None     Document Type: Article

References (51)

1. Nestler EJ, Barrot M, Dileone RJ, Eisch AJ, Gold SJ, Monteggia LM. Neurobiology of depression. Neuron 2002; 34: 13-25.
2. Farida A, Singh PP, Manoj, Anil K, Gaur RK. Drug prescribing for major depressive psychosis patients in geriatric clinic of a teaching hospital in northern India. Indian J Pharm Sci 2013; 5: 269-272.
3. Berton O, Nestler EJ. New approaches to antidepressant drug discovery: beyond monoamines. Nature Reviews Neuroscience 2006; 7: 137-151.
4. Duman RS. Depression: A case of neuronal life and death? Biol Psychiatry 2004; 56: 140-145.
5. Blier P. The pharmacology of putative early-onset antidepressant strategies. Eur Neuropsychopharmacol 2003; 13: 57-66.
6. Rajkumar R and Mahesh R. Assessing the neuronal serotonergic target-based anti-depressant stratagem. Impact of invivo interaction studies and knockout models. Curr Neuropharmacol 2008; 6: 215-234.
7. Hoyer D, Hennen JP, Martin GR. Molecular, pharmacological and functional diversity of 5-HT receptors. Pharmacol Biochem Behav 2002; 71: 533-554.
8. Vanpraag HM. Can stress cause depression. Prog Neuropsychopharmacol Biol 2004; 28: 897-907.
9. Barnes NM, Sharp T. A review of central 5-HT receptors and their function. Neuropharmacology 1999; 38: 1083-1152.
10. Mahesh R, Perumal RV, Pandi PV. Cancer chemotherapy induced nausea and vomiting: Role of mediators, development of drugs and treatment methods. Pharmazie 2005; 60: 83-96.
11. 3 receptor Antagonists. Scand J Rheumatol 2000; 29: 37-45.
12. 3 receptors in the control of 5-HT release in rat hippocampus in vivo. Br J Pharmacol 1992; 106: 139-142.
13. Rajkumar R, Mahesh R, Borah M. Antidepressant-like effects of serotonin type-3 antagonist, ondansetron: An investigation in behaviour-based rodent models. Behav Pharmacol 2008; 19: 29-40.
14. 3 receptors in the activity of antidepressants in the mouse forced swimming test. Eur J Pharmacol 1997; 325: 129-135.
15. 3 receptor-mediated effect in the raphe nuclei of the rat. Brain Res Bull 1998; 45: 203-208.
16. 3 and 5-HT4 receptors. Br J Pharmacol 1995; 114: 1017-1025.
17. Varea E, Blasco-Ibanez JM, Gomez-Climent MA, Castillo-Gomez E, Crespo C, Martinez-Guijarro FJ, Nacher J. Chronic fluoxetine treatment increases the expression of PSANCAM in the medial prefrontal cortex. Neuropsychopharmacology 2007; 32: 803-812.
18. 3 receptor antagonists ameliorate fatigue: so much potential, so little knowledge. Gut 2005; 54: 1056-1057.
19. Gibbs IS, Heald A, Jacobson H, Wadke D, Weliky I. Physical characterization and activity in vivo of polymorphic forms of 7-chloro-5, 11-dihydrodibenz [b, e][1, 4] oxazepine-5-carboxamide, a potential tricyclic anti-depressant. J Pharm Sci 1976; 65: 1380-1385.
20. Hadizadeh F, Hosseinzadeh H, Motamed-Shariaty Sadat V, Seifi M, Kazemi S. Synthesis and anti-depressant activity of N-substituted imidazole-5-carboxamides in forced swimming test model. Iran J Pharm Res 2008; 7: 29-33.
21. Pessoa-Mahana H, Rodrigo AR, Ramiro AM, Claudio SB, Pessoa-Mahana CD. Synthesis of benzo[b]thiophene carboxamides connected to 4-aryl piperazines through a benzylic spacer; potential ligands with 5-HT1a binding affinity. Synth Commun 2007; 37: 3559-3567.
22. Pathan AR, Viswanad B, Sonkusare SK, Ramarao P. Chronic administration of pioglitazone attenuates intracerebroventricular streptozotocin induced-memory impairment in rats. Life Sci 2006; 79: 2209-2216.
23. Chandrashekar R, Manohar VR, Rao SN. Antidepressant activity of aqueous extract of fruits of terminalia chebula in rats. Indian J Pharm Sci 2012; 4: 449-451.
24. Pandey DK, Rajkumar R, Mahesh R, Radha R. Depressant-like effect of parthenolide in a rodent behavioural anti-depressant test battery. J Pharm Pharmacol 2008; 60: 1643-1650.
25. Steru L, Chermat R, Thierry B, Simon P. The tail suspension test: A new method for screening anti-depressants in mice. Psychopharmacology (Berl) 1985; 85: 367-370.
26. O'Leary OF, Bechthold AJ, Crowley JJ, Hill TE, Page ME, Lucki I. Depletion of serotonin and catecolamines block the acute behavioral response to different classes of anti-depressant drugs in the mouse tail suspension test. Psychopharmacology (Berl) 2007; 192: 357-371.
27. Heal DJ, Philpot J, O'Shaughnessy KM, Davies CL. The influence of central noradrenergic function on 5-HT-mediated head-twitch responses in mice: possible implications for the actions of antidepressantdrugs. Psychopharmacology (Berl) 1986; 89: 414420-414425.
28. 3 receptor antagonist, in animal models of depression. Pharmacol Rep 2010; 62: 245-257.
29. Costa E, Garatini S, Valzelli L. Interaction between reserpine, imipramine and chlorpromazine. Experientia 1960; 16: 461-463.
30. Ivan S, Tomislav K, Mirko D. Neurochemical and Behavioural Changes in Rat Models of Depression. Croat Chem Acta 2011; 84: 287-299.
31. Tasset I, Medina FJ, Penaz J, Jimena I, Del M, Saldedo M et al. Olfactory Bulbectomy Induced Oxidative and Cell Damage in Rat: Protective Effect of Melatonin. Physiol Res 2010; 59: 105-112.
32. Song C, Leonard BE. The olfactory bulbectomised rat as a model of depression. Neurosci Biobehav Res 2005; 29: 627-647.
33. Casarotto PC, Andreatini R. Repeated paroxetine treatment reverses anhedonia induced inrats by chronic mild stress or dexamethasone. Eur Neuropsychopharmacol 2007; 17: 735-742.
34. Luo DD, An SC, Zhang X. Involvement of hippocampal serotonin and neuropeptide Y in depression induced by chronic unpredicted mild stress. Brain Res Bull 2008; 77:8-12.
35. Klein D, Brown TS. Exploratory behavior and spontaneous alteration in blind and anosmic rats. J Comp Physiol Psychol 1969; 68: 107-110.
36. Kelly JP, Wyrnn AS, Leonard BE. Olfactory bulbectomized rat as a model of depression: An update. Pharmacol Ther 1997; 74: 299-316.
37. Van Reizen H, Leonard BE. Effects of psychotropic drugs on the behavior and neurochemistry of olfactory Bulbectomised rats. Pharmacol Ther 1990; 47: 21-34.
38. Boissier JR, Simon P. Action of caffeine on the spontaneous motility of the mouse. Arch Int Pharmacodyn Ther 1965; 158: 212-221.
39. Thiebot MH, Martin P, Puech AJ. Animal behavioural studies in the evaluation of antidepressant drugs. Br J Psychiatry 1992; 160: 44-50.
40. Willner P. Animal models of depression: An overview. Pharmacol Ther 1990; 45: 425-455.
41. Detke MJ, Rickels M, Lucki I. Active behaviors in the rat forced swimming test differentially produced by serotonergic and noradrenergic antidepressants. Psychopharmacology (Berl) 1995; 121: 66-72.
42. Lucki I. The forced swimming test as a model for core and component behavioral effects of antidepressant drugs. Behav Pharmacol 1997; 8: 523-532.
43. 9-tetra-hydrocannabinol on Reserpine-induced hypothermia in rats. Br J Pharmacol 1973; 49: 243-252.
44. Kalueff AV, Gallagher PS, Murphy DL. Are serotonin transporter knockout mice 'depressed'?: hypoactivity but no anhedonia. Neuroreport 2006; 17: 1347-1351.
45. Strekalova T, Gorenkova N, Schunk E, Dolgov O, Bartsch D. Selective effects of citalopram in a mouse model of stress-induced anhedonia with a control for chronic stress. Behav Pharmacol 2006; 17: 271-287.
46. Bekris S, Antoniou K, Daskas S, Papadopoulou-Daifoti Z. Behavioural and neurochemical effects induced by chronic mild stress applied to two different rat strains. Behav Brain Res 2005; 161: 45-59.
47. Lumia AR, Teicher MH, Salchli F, Ayers E, Possidente B. Olfactory bulbectomy as a model for agitated hyposerotonergic depression. Brain Res 1992; 587: 181-185.
48. Bourin M, Fiocco AJ, Clenet F. How valuable are animal models in defining anti-depressant activity? Human Psychopharmacol 2001; 16: 9-21.
49. Schafer WR. How do antidepressant work? Prospect for genetic analysis of drug mechanism. Cell 1999; 98: 551-554.
50. Greenshaw AJ. Behavioral pharmacology of 5-HT, receptor antagonists: A critical uptake on therapeutic potential. Trends Pharmacol Sci 1992; 14: 265-270.
51. Kilpatrick GJ, Butler A, Ireland SJ, Michel AD, Tyers MB. Affinities of 5-HT uptake inhibitors for 5-HT, receptors in both binding and functional studies. Br J Pharmacol 1989; 98: Suppl 859P.